• Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 210.56%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.61
▼ -0.05 (-3.01%)

This chart shows the closing price for PSNL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Personalis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSNL

Analyst Price Target is $5.00
▲ +210.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Personalis in the last 3 months. The average price target is $5.00, with a high forecast of $7.50 and a low forecast of $3.50. The average price target represents a 210.56% upside from the last price of $1.61.

This chart shows the closing price for PSNL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Personalis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$3.50 ➝ $3.50Low
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$3.50Low
4/30/2024Lake Street CapitalInitiated CoverageBuy$4.00Low
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$3.50Low
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$2.30 ➝ $3.50Low
1/5/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$2.30Low
11/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$7.00 ➝ $2.30Low
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$7.00Low
8/9/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $7.50Low
2/27/2023Morgan StanleyLower TargetEqual Weight$11.00 ➝ $5.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$8.00Low
2/24/2023HC WainwrightLower TargetBuy$13.00 ➝ $10.00Low
2/6/2023Needham & Company LLCUpgradeHold ➝ Buy$8.00Low
11/4/2022Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00Low
11/3/2022CitigroupLower TargetBuy$8.00 ➝ $6.00Low
11/3/2022HC WainwrightLower TargetBuy$26.00 ➝ $13.00Low
8/9/2022BTIG ResearchLower Target$11.00Low
8/4/2022HC WainwrightLower TargetBuy$30.00 ➝ $26.00N/A
5/5/2022CitigroupLower Target$18.00 ➝ $14.00High
5/5/2022HC WainwrightLower Target$38.00 ➝ $30.00High
2/25/2022OppenheimerLower TargetOutperform$30.00 ➝ $24.00Low
2/25/2022HC WainwrightLower TargetBuy$50.00 ➝ $38.00High
2/25/2022CitigroupLower TargetBuy$30.00 ➝ $18.00High
1/7/2022BTIG ResearchReiterated RatingBuy$30.00High
1/7/2022Bank of AmericaUpgradeNeutral ➝ Buy$27.00 ➝ $23.00High
11/5/2021BTIG ResearchReiterated RatingBuy$29.00Low
11/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$32.00 ➝ $25.00High
11/3/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
9/23/2021HC WainwrightReiterated RatingBuy$50.00Low
9/21/2021BTIG ResearchLower TargetBuy$35.00 ➝ $30.00High
9/20/2021Needham & Company LLCLower TargetBuy$33.00 ➝ $28.00Medium
8/5/2021CitigroupLower TargetBuy$37.00 ➝ $30.00High
5/13/2021Truist FinancialLower TargetBuy ➝ Buy$37.00 ➝ $29.00High
5/7/2021Morgan StanleyLower TargetOverweight$38.00 ➝ $35.00High
5/6/2021Needham & Company LLCLower TargetBuy$38.00 ➝ $33.00High
5/6/2021OppenheimerUpgradeMarket Perform ➝ Outperform$28.00High
4/14/2021OppenheimerReiterated RatingHoldMedium
3/1/2021Morgan StanleyBoost TargetOverweight$27.00 ➝ $38.00Low
2/26/2021Needham & Company LLCReiterated RatingBuy$38.00High
1/27/2021Truist FinancialInitiated CoverageBuy$50.00High
1/13/2021HC WainwrightBoost TargetBuy$30.00 ➝ $50.00Low
1/12/2021OppenheimerReiterated RatingHoldHigh
1/4/2021Bank of AmericaDowngradeBuy ➝ Neutral$40.00N/A
12/16/2020Smith Barney CitigroupBoost Target$35.00 ➝ $45.00Low
11/12/2020Needham & Company LLCBoost TargetIn-Line ➝ Buy$25.00 ➝ $32.00Low
11/9/2020Morgan StanleyBoost TargetOverweight$25.00 ➝ $27.00High
11/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformHigh
10/19/2020Smith Barney CitigroupInitiated CoverageBuy$35.00Medium
10/7/2020BTIG ResearchInitiated CoverageBuy$35.00Medium
9/23/2020HC WainwrightReiterated RatingBuy$30.00High
8/27/2020HC WainwrightInitiated CoverageBuy$30.00Medium
8/17/2020Needham & Company LLCInitiated CoverageBuy$25.00Low
8/7/2020Morgan StanleyBoost TargetOverweight$14.00 ➝ $25.00Low
6/24/2020OppenheimerInitiated CoverageBuy$24.00High
5/8/2020Morgan StanleyBoost TargetOverweight$13.00 ➝ $14.00High
5/7/2020OppenheimerInitiated CoverageBuy$24.00Medium
4/21/2020OppenheimerInitiated CoverageBuy$24.00Medium
3/26/2020Morgan StanleyLower TargetOverweight$16.00 ➝ $13.00Low
11/14/2019OppenheimerLower TargetOutperform$29.00 ➝ $26.00High
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$22.00High
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/19/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/17/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Personalis logo
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $1.61
Low: $1.61
High: $1.73

50 Day Range

MA: $1.38
Low: $1.17
High: $1.70

52 Week Range

Now: $1.61
Low: $0.89
High: $2.43

Volume

254,391 shs

Average Volume

342,467 shs

Market Capitalization

$83.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Personalis?

The following Wall Street sell-side analysts have issued reports on Personalis in the last year: HC Wainwright, Lake Street Capital, and Needham & Company LLC.
View the latest analyst ratings for PSNL.

What is the current price target for Personalis?

3 Wall Street analysts have set twelve-month price targets for Personalis in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 210.6%. HC Wainwright has the highest price target set, predicting PSNL will reach $7.50 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $3.50 for Personalis in the next year.
View the latest price targets for PSNL.

What is the current consensus analyst rating for Personalis?

Personalis currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSNL will outperform the market and that investors should add to their positions of Personalis.
View the latest ratings for PSNL.

What other companies compete with Personalis?

How do I contact Personalis' investor relations team?

Personalis' physical mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company's listed phone number is (650) 752-1300 and its investor relations email address is [email protected]. The official website for Personalis is www.personalis.com. Learn More about contacing Personalis investor relations.